Francesco Catamerò

Dr. Francesco Catamerò

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2026 in Allergy
Verified
Journal Article
Open access
RVRafael José Vieira
Rafael José Vieira
BSBernardo Sousa‐Pinto
Bernardo Sousa‐Pinto
Jean BousquetJean Bousquet
Jean Bousquet
HSHolger J. Schünemann
Holger J. Schünemann
Torsten ZuberbierTorsten Zuberbier
Torsten Zuberbier
JFJoão A. Fonseca
João A. Fonseca
Background: Oral and ocular medications are frequently used in the treatment of allergic rhinitis (AR). As part of the update of the Allergic Rhinitis and its Impact on Asthma (ARIA)‐EAACI guidelines, this manuscript presents the ARIA‐EAACI 2024–2025 recommendations for oral and ocular treatments. Methods: The ARIA‐EAACI 2024–2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) evidence‐to‐decision framework. Several sources of evidence were used to inform panel judgements and recommendations, including systematic reviews, mHealth and pharmacovigilance data as well as a survey on costs. Results: Eight guideline questions concerning oral treatments for AR and three questions concerning ocular treatments were addressed. These questions led to the recommendations. Overall, these questions concern the choice between different classes of medication. They also discuss the role of oral antihistamines (OAH), leukotriene receptor antagonists (LTRA), ocular antihistamines (OcAH) and ocular mast cell stabilisers. Four questions had not been previously evaluated in ARIA guidelines, while, for the other four, there was a change in the strength or directionality of the recommendations. Overall, these guidelines recommend using intranasal corticosteroids over OAH and using OAH over LTRA. Moreover, they suggest using OAH over OcAH and suggest being against adding LTRA to OAH. Finally, considerations for choosing between different individual OAHs are presented. Conclusion: This ARIA‐EAACI 2024–2025 article supports patients, their caregivers and healthcare professionals in choosing oral and ocular treatments for AR. Decisions on treatment should consider the clinical variability of the disease, patients' values and the affordability of medications.

22 April 2024 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
Simone Foti RandazzeseSimone Foti Randazzese
Simone Foti Randazzese
IPIlenia Panasiti
Ilenia Panasiti
LCLucia Caminiti
Lucia Caminiti
FCFrancesco Catamerò
Francesco Catamerò
MLMassimo Landi
Massimo Landi
SBSalvatore Barberi
Salvatore Barberi

24 April 2025 in Blood Advances
Verified
Journal Article
Open access
FPFrancesco Pegoraro
Francesco Pegoraro
FCFrancesco Catamerò
Francesco Catamerò
FAFederica Allegretta
Federica Allegretta
GPGiulia Palazzini
Giulia Palazzini
FPFrancesco Peyronel
Francesco Peyronel
AVAugusto Vaglio
Augusto Vaglio

23 April 2025 in Leukemia
Verified
Journal Article
Open access
PDF file
FPFrancesco Pegoraro
Francesco Pegoraro
FCFleur Cohen-Aubart
Fleur Cohen-Aubart
MPMatthias Papo
Matthias Papo
FCFrancesco Catamerò
Francesco Catamerò
JRJerome Razanamahery
Jerome Razanamahery
JHJulien Haroche
Julien Haroche

28 May 2025 in Leukemia
Verified
Journal Article
Closed access
PDF file
MTMichelangelo Tesi
Michelangelo Tesi
FPFrancesco Pegoraro
Francesco Pegoraro
FPFrancesco Peyronel
Francesco Peyronel
JEJean-François Emile
Jean-François Emile
FCFrancesco Catamerò
Francesco Catamerò
JHJulien Haroche
Julien Haroche

23 May 2025 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
FCFrancesco Catamerò
Francesco Catamerò
MGMattia Giovannini
Mattia Giovannini
SBsimona barni
simona barni
GLGiulia Liccioli
Giulia Liccioli
LSLucrezia Sarti
Lucrezia Sarti
Francesca MoriFrancesca Mori
Francesca Mori
House dust mite (HDM) is the most common cause of perennial allergy worldwide, causing allergic rhinitis with or without conjunctivitis (AR/C). HDM-related clinical manifestations can be treated with allergy pharmacotherapy or allergen immunotherapy (AIT) in selected cases. AIT is acknowledged as the only therapeutic approach capable of modifying the course of allergic diseases. SQ HDM-SLIT tablets (Accarizax; Merck & Co, Kenilworth, NJ/ALK-Abellò, Hørsholm, Denmark) ensures a constant potency ratio of major HDM allergens of the Dermatophagoides pteronyssinus (DERM_PT) and Dermatophagoides farinae (DERM_FA) HDM species and has demonstrated beneficial effects on allergic rhinoconjunctivitis outcomes. In Italy, rhinoconjunctivitis affects up to as many as 40% of adolescents, but no studies on HDM AIT quality of life (QoL) regarding this exclusive cohort of patients have been specifically conducted. The aim of this study is to evaluate SQ HDM SLIT tablets’ performance in improving QoL in Italian adolescents. To assess the treatment at T0, T1, and T2, we employed the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ(s)), a standardized self-administered questionnaire designed for Italian patients aged 12 and above. RQLQ(s) median values at T2 and T1 were significantly lower than those at T0 (p-values equal to 0.0018 and 0.0051 for T0 vs. T2 and T0 vs. T1, respectively). Our findings suggest that the QoL of SQ HDM SLIT tablet is highly promising, demonstrating substantial potential in alleviating signs and symptoms. Our data suggest that QoL significantly improved with SQ-HDM SLIT, highlighting the potential importance of introducing this therapy for selected cases.